Inverse Agonist Activity of Angiotensin II Receptor Blocker Is Crucial for Prevention of Progressive Aortic Dilatation in Marfan Syndrome
Arteriosclerosis, Thrombosis, and Vascular Biology · 2026-01 · 46 (1) · 132-144
DOI: 10.1161/atvbaha.125.322646 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arteriosclerosis, Thrombosis, and Vascular Biology, 2026-01. Verfasst von Hiroki Yagi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine (H.Y., H.A., Q.L., M.U., H.K., R.M., A.S., S.O., T.U., A.S.-K., K.U., N.T.), Graduate School of Medicine, the U…. Hauptthemen laut MEDLINE: Marfan Syndrome, Benzimidazoles, Biphenyl Compounds, Angiotensin II Type 1 Receptor Blockers. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 60 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Marfan syndrome is an inherited disorder caused by FBN1 gene mutations, which can lead to thoracic aortic aneurysm and dissection. Selective AT 1 (angiotensin II type 1) receptor blockade is a preventive option against Marfan syndrome aortopathy, and recent clinical studies demonstrated that the inhibitory effect of an ARB (AT 1 receptor blocker) losartan on aortic aneurysm growth is equivalent to that of β-blockers. At present, several ARBs are clinically available, and they have drug-specific differences in pharmacological properties. Especially, inverse agonism of ARBs has potential benefits for cardiovascular protection, but its impact on Marfan syndrome aortopathy remains poorly understood. METHODS: Candesartan-7H is a candesartan derivative that lacks the carboxyl group critical for inverse agonist activity and works as a neutral antagonist for the AT 1 receptor. Candesartan cilexetil (1 mg/kg per day), candesartan-7H (1 or 20 mg/kg per day), or vehicle was administered to Fbn1 C1041G/+ mice, and aortic dilatation was analyzed using echocardiography, histological staining, and in situ MMP (matrix metalloproteinase) assay. Activation of TGF-β (transforming growth factor β) signaling and mechanosensitive signaling was studied using Western blot and immunohistochemical analysis. RESULTS: Candesartan cilexetil (1 mg/kg per day) and candesartan-7H (20 mg/kg per day) lowered blood pressures equally in Fbn1 C1041G/+ mice. Progressive dilatation of the aorta in association with aortic wall thickening, degeneration of elastic fibers, deposition of collagen, MMP activation, and TGF-β signaling activation in Fbn1 C1041G/+ mice was significantly suppressed by treatment with candesartan cilexetil (1 mg/kg per day), but not by candesartan-7H, even at 20 mg/kg per day. In addition, candesartan cilexetil, but not candesartan-7H, suppressed activation of mechanosensitive signaling involving focal adhesion kinase, p38 mitogen-activated protein kinase, and early growth response-1 in the ascending aorta of Fbn1 C1041G/+ mice. CONCLUSIONS: Our findings support a crucial role of inverse agonist activity of ARB for the prevention of mechanical stress-induced AT 1 receptor activation and aortic aneurysm progression in Marfan syndrome mice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine (H.Y., H.A., Q.L., M.U., H.K., R.M., A.S., S.O., T.U., A.S.-K., K.U., N.T.), Graduate School of Medicine, the University of Tokyo, Japan.
- Marfan Syndrome Center (H.Y., N.T.), the University of Tokyo Hospital, Tokyo, Japan.
- International Medical Center of Zhongshan Hospital, Fudan University, Shanghai, China (Q.L.).
- Department of Pharmacy (S.M.I., T.T.), the University of Tokyo Hospital, Tokyo, Japan.
- Cardiovascular Biobank Research Center, International University of Health and Welfare, Tokyo, Japan (K.U., I.K.).
- Department of Frontier Cardiovascular Science (I.K.), Graduate School of Medicine, the University of Tokyo, Japan.
ORCID-Profile: Hiroki Yagi, Hiroshi Akazawa, Qing Liu, Masahiko Umei, Hiroshi Kadowaki, Akito Shindo, Shun Okamura, Tomomi Ueda, Akiko Saga-Kamo, Kazutaka Ueda, Norifumi Takeda, Tappei Takada, Issei Komuro
Zitieren
APA
Yagi, H., Akazawa, H., Liu, Q., Ito, S. M., Umei, M., Kadowaki, H., Matsuoka, R., Shindo, A., Okamura, S., Ueda, T., Saga-Kamo, A., Ueda, K., Takeda, N., Takada, T., & Komuro, I. (2026). Inverse Agonist Activity of Angiotensin II Receptor Blocker Is Crucial for Prevention of Progressive Aortic Dilatation in Marfan Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology, 46(1), 132-144. https://doi.org/10.1161/atvbaha.125.322646
Vancouver
Yagi H, Akazawa H, Liu Q, Ito SM, Umei M, Kadowaki H, et al. Inverse Agonist Activity of Angiotensin II Receptor Blocker Is Crucial for Prevention of Progressive Aortic Dilatation in Marfan Syndrome. Arteriosclerosis, Thrombosis, and Vascular Biology. 2026;46(1):132-144. doi:10.1161/atvbaha.125.322646
BibTeX
@article{Yagi2026,
author = {Yagi, Hiroki and Akazawa, Hiroshi and Liu, Qing and Ito, Sayo M and Umei, Masahiko and Kadowaki, Hiroshi and Matsuoka, Ryo and Shindo, Akito and Okamura, Shun and Ueda, Tomomi and Saga-Kamo, Akiko and Ueda, Kazutaka and Takeda, Norifumi and Takada, Tappei and Komuro, Issei},
title = {Inverse Agonist Activity of Angiotensin II Receptor Blocker Is Crucial for Prevention of Progressive Aortic Dilatation in Marfan Syndrome},
journal = {Arteriosclerosis, Thrombosis, and Vascular Biology},
year = {2026},
volume = {46},
number = {1},
pages = {132--144},
doi = {10.1161/atvbaha.125.322646}
}
EUVIMED